title: Transferrin conjugation does not increase the efficiency of liposomal Foscan during in vitro photodynamic therapy of oesophageal cancer.
abstract: Photodynamic therapy (PDT) is based on the delivery of photocytotoxic agents to a target tissue, followed by irradiation. In order to increase the efficiency of PDT in oesophageal cancer therapy, polyethylene glycol (PEG)-grafted, transferrin (Tf)-conjugated liposome formulations of 5,10,15,20-tetra(m-hydroxyphenyl)chlorin (Foscan), a second-generation photosensitiser, were prepared. Expression of transferrin receptors (CD71) in the oesophageal cancer cell line, OE21, was confirmed by immunoblot and confocal laser scanning microscopy. The anti-proliferative effect of Foscan liposomes was evaluated and compared with plain formulations (i.e., without Tf) as well as with free drug. In addition, the intracellular accumulation was studied using high content analysis. Surprisingly, delivering Foscan by transferrin-conjugated PEG-liposomes to oesophageal cancer cells did not improve the photocytotoxicity or the intracellular accumulation of Foscan when compared to unmodified liposomes or indeed free photosensitiser. Tf-targeted drugs and drug delivery systems have shown improved the therapy of many cancers. Our study, however, did not corroborate these findings. If this is due to the tumour type, the choice of in vitro model or the delivery systems remains to be confirmed.
authors.affiliation: Institute of Molecular Medicine, Medicinal Chemistry, Trinity Centre for Health Sciences, Trinity College Dublin, St. James's Hospital, Dublin 8, Ireland.
authors.forename: Edyta
authors.initials: E
authors.lastname: Paszko
authors.forename: Gisela M F
authors.initials: GM
authors.lastname: Vaz
authors.forename: Carsten
authors.initials: C
authors.lastname: Ehrhardt
authors.forename: Mathias O
authors.initials: MO
authors.lastname: Senge
mesh_terms: D015060:1,2-Dipalmitoylphosphatidylcholine / Q000031:analogs & derivatives / Q000737:chemistry; D015703:Antigens, CD / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004938:Esophageal Neoplasms / Q000188:drug therapy; D006801:Humans; D008081:Liposomes; D008652:Mesoporphyrins / Q000008:administration & dosage*; D010715:Phosphatidylglycerols / Q000737:chemistry; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011092:Polyethylene Glycols / Q000737:chemistry; D011990:Receptors, Transferrin / Q000378:metabolism; D014168:Transferrin / Q000008:administration & dosage* / Q000737:chemistry
chemical_list: D015703:Antigens, CD; D000970:Antineoplastic Agents; C068126:CD71 antigen; D008081:Liposomes; D008652:Mesoporphyrins; D010715:Phosphatidylglycerols; D017319:Photosensitizing Agents; D011990:Receptors, Transferrin; D014168:Transferrin; D015060:1,2-Dipalmitoylphosphatidylcholine; C081581:colfosceril palmitate; D011092:Polyethylene Glycols; C072269:temoporfin; C030345:1,2-dipalmitoylphosphatidylglycerol